As a late clinical-stage biopharmaceutical company focused on oncology, our business model is to in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development and/or commercialization.

Our lead program, Motixafortide (BL-8040), is a cancer therapy platform that was successfully evaluated in a Phase 3 study in stem cell mobilization for autologous bone-marrow transplantation, and has reported positive results from a pre-planned pharmacoeconomic study. These outstanding results support the goal of Motixafortide becoming the standard of care mobilization agent in autologous bone-marrow transplantation, and in this regard we are currently preparing an NDA more